



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The General Manager National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051	The General Manager Bombay Stock Exchange Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400 001
--	--

IOLCP/CGC/2018
16 May2018

Subject: Disclosure under Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release

Dear Sir,

Pursuant to Regulations 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release with respect to Financial Results for the Quarter and Financial Year ended on 31 March 2018. The same is also available on the website of the Company i.e. www.iolcp.com.

This is for your information & record please.

Thanking You

Yours faithfully
For IOL Chemicals and Pharmaceuticals Limited



(Krishan Singh)
Vice President and Company Secretary

For immediate release

Press Release

IOL Chemicals and Pharmaceuticals Ltd reports remarkable performance and achieved Revenue of ₹ 1000 crore

Revenue from operations (QoQ) increased by 39% and (YoY) increased by 29%
Net Profit (QoQ) increased to ₹ 11.49 crore from ₹ 2.00 crore
Net Profit (YoY) increased to ₹ 27.70 crore from ₹ 4.67 crore

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals posted remarkable operational and financial performance for the quarter and year ended 31 March 2018.

Revenue from operations increased by 38.51% during quarter ended 31 March 2018 to ₹ 287.52 crore from ₹ 207.58 crore during the corresponding quarter of the previous year.

The Company has earned net profit after tax of ₹ 11.49 crore during quarter ended 31 March 2018 against ₹ 2.00 crore during the corresponding quarter of the previous year. The operating profit for quarter ended 31 March 2018 went up to ₹ 35.44 crore as against operating profit of ₹ 26.49 crore reported in the corresponding quarter ended 31 March 2017.

Revenue from operations increased by 29.46% to ₹ 1000.96 crore during financial year ended 31 March 2018 from ₹ 773.19 crore during financial year ended 31 March 2017.

The Company has earned net profit after tax of ₹ 27.70 crore during financial year ended 31 March 2018 against ₹ 4.67 crore during financial year ended 31 March 2017. The operating profit during financial year ended 31 March 2018 went up to ₹ 125.86 crore as against operating profit of ₹ 103.45 crore during financial year ended 31 March 2017.

The Ibuprofen manufacturing facilities have been approved by US Food and Drug Administration (USFDA), EDQM, WHO. The Company is already exporting its Ibuprofen to regulated & Emerging markets i.e. Europe, Latin America, Middle East, etc



About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and National Stock Exchange (Code: IOLCP) is one of the leading APIs Company, and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, Anti diabetes, Anti hypertensive, Anti Convulsants.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 7200TPA and having backward integrated manufacturing facility at one location. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) was set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including Austria, Belgium, Hungary, Spain, Switzerland, Portugal, Poland, Ireland, USA, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand, Iran etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

